No association between antidepressant efficacy and rs28365143 in corticotropin-releasing hormone binding protein in a large meta-analysis

Chiara Fabbri; Cathryn M. Lewis; Roy H. Perlis; Rudolf Uher

doi:10.1176/appi.ajp.2018.18010070

No association between antidepressant efficacy and rs28365143 in corticotropin-releasing hormone binding protein in a large meta-analysis

Chiara Fabbri, Cathryn M. Lewis, Roy H. Perlis, Rudolf Uher

Medicine

Medicine

Producción científica: Contribución a una revista › Carta › revisión exhaustiva

1 Cita (Scopus)

Idioma original	English
Páginas (desde-hasta)	575-576
Número de páginas	2
Publicación	American Journal of Psychiatry
Volumen	175
N.º	6
DOI	https://doi.org/10.1176/appi.ajp.2018.18010070
Estado	Published - jun. 2018

Nota bibliográfica

Funding Information:
The STAR*D study was supported by NIMH Contract N01MH90003 to the University of Texas Southwestern Medical Center (ClinicalTrials.gov identifier: NCT00021528). The GENDEP project was supported by a European Commission Framework 6 grant (contract reference: LSHB-CT-2003-503428). The Medical Research Council, United Kingdom, and GlaxoSmithKline (G0701420) provided support for genotyping. The NEWMEDS study was funded by the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under grant agreement 115008, resources of which are from in-kind contributions from the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), as well as financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013). EFPIA members Pfizer, GlaxoSmithKline, and F. Hoffmann–La Roche have contributed work and samples to the project presented here. The funders had no role in study design, data collection and analysis, the decision to publish, or in the preparation of the manuscript. The Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data set used for the analyses described in this letter was obtained from the dbGaP (study accession phs000670.v1.p1). The PGRN-AMPS was supported in part by NIH grants RO1 GM28157, U19 GM61388 (The Pharmacogenomics Research Network), U01 HG005137, R01 CA138461, and P20 1P20AA017830-01 (The Mayo Clinic Center for Individualized Treatment of Alcohol Dependence) and by a PhRMA Foundation Center of Excellence in Clinical Pharmacology award.

ASJC Scopus Subject Areas

Psychiatry and Mental health

PubMed: MeSH publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1176/appi.ajp.2018.18010070

Otros archivos y enlaces

Citar esto

@article{3a1da5273da94e0794f6e349839e34a0,

title = "No association between antidepressant efficacy and rs28365143 in corticotropin-releasing hormone binding protein in a large meta-analysis",

author = "Chiara Fabbri and Lewis, {Cathryn M.} and Perlis, {Roy H.} and Rudolf Uher",

note = "Funding Information: The STAR*D study was supported by NIMH Contract N01MH90003 to the University of Texas Southwestern Medical Center (ClinicalTrials.gov identifier: NCT00021528). The GENDEP project was supported by a European Commission Framework 6 grant (contract reference: LSHB-CT-2003-503428). The Medical Research Council, United Kingdom, and GlaxoSmithKline (G0701420) provided support for genotyping. The NEWMEDS study was funded by the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under grant agreement 115008, resources of which are from in-kind contributions from the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), as well as financial contribution from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013). EFPIA members Pfizer, GlaxoSmithKline, and F. Hoffmann–La Roche have contributed work and samples to the project presented here. The funders had no role in study design, data collection and analysis, the decision to publish, or in the preparation of the manuscript. The Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data set used for the analyses described in this letter was obtained from the dbGaP (study accession phs000670.v1.p1). The PGRN-AMPS was supported in part by NIH grants RO1 GM28157, U19 GM61388 (The Pharmacogenomics Research Network), U01 HG005137, R01 CA138461, and P20 1P20AA017830-01 (The Mayo Clinic Center for Individualized Treatment of Alcohol Dependence) and by a PhRMA Foundation Center of Excellence in Clinical Pharmacology award.",

year = "2018",

month = jun,

doi = "10.1176/appi.ajp.2018.18010070",

language = "English",

volume = "175",

pages = "575--576",

journal = "American Journal of Psychiatry",

issn = "0002-953X",

publisher = "American Psychiatric Association",

number = "6",

}

TY - JOUR

T1 - No association between antidepressant efficacy and rs28365143 in corticotropin-releasing hormone binding protein in a large meta-analysis

AU - Fabbri, Chiara

AU - Lewis, Cathryn M.

AU - Perlis, Roy H.

AU - Uher, Rudolf

N1 - Funding Information: The STAR*D study was supported by NIMH Contract N01MH90003 to the University of Texas Southwestern Medical Center (ClinicalTrials.gov identifier: NCT00021528). The GENDEP project was supported by a European Commission Framework 6 grant (contract reference: LSHB-CT-2003-503428). The Medical Research Council, United Kingdom, and GlaxoSmithKline (G0701420) provided support for genotyping. The NEWMEDS study was funded by the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under grant agreement 115008, resources of which are from in-kind contributions from the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), as well as financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013). EFPIA members Pfizer, GlaxoSmithKline, and F. Hoffmann–La Roche have contributed work and samples to the project presented here. The funders had no role in study design, data collection and analysis, the decision to publish, or in the preparation of the manuscript. The Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data set used for the analyses described in this letter was obtained from the dbGaP (study accession phs000670.v1.p1). The PGRN-AMPS was supported in part by NIH grants RO1 GM28157, U19 GM61388 (The Pharmacogenomics Research Network), U01 HG005137, R01 CA138461, and P20 1P20AA017830-01 (The Mayo Clinic Center for Individualized Treatment of Alcohol Dependence) and by a PhRMA Foundation Center of Excellence in Clinical Pharmacology award.

PY - 2018/6

Y1 - 2018/6

UR - http://www.scopus.com/inward/record.url?scp=85048069809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048069809&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2018.18010070

DO - 10.1176/appi.ajp.2018.18010070

M3 - Letter

C2 - 29869543

AN - SCOPUS:85048069809

SN - 0002-953X

VL - 175

SP - 575

EP - 576

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

IS - 6

ER -